Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 2039

1.

Oral cannabinoids in people living with HIV on effective antiretroviral therapy: CTN PT028-study protocol for a pilot randomised trial to assess safety, tolerability and effect on immune activation.

Costiniuk CT, Saneei Z, Routy JP, Margolese S, Mandarino E, Singer J, Lebouché B, Cox J, Szabo J, Brouillette MJ, Klein MB, Chomont N, Jenabian MA.

BMJ Open. 2019 Jan 17;9(1):e024793. doi: 10.1136/bmjopen-2018-024793.

PMID:
30659041
2.

Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from postapproval pragmatic studies.

Patti F.

Neurodegener Dis Manag. 2019 Jan 18. doi: 10.2217/nmt-2018-0049. [Epub ahead of print]

PMID:
30657027
3.

Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from randomized clinical trials.

Marková J.

Neurodegener Dis Manag. 2019 Jan 18. doi: 10.2217/nmt-2018-0050. [Epub ahead of print]

PMID:
30657024
4.

Tetrahydrocannabinol: cannabidiol oromucosal spray for treating symptoms of multiple sclerosis spasticity: newest evidence.

Ziemssen T.

Neurodegener Dis Manag. 2019 Jan 18. doi: 10.2217/nmt-2018-0048. [Epub ahead of print]

PMID:
30657019
5.

Discovering the pharmacodynamics of conolidine and cannabidiol using a cultured neuronal network based workflow.

Mendis GDC, Berecki G, Morrisroe E, Pachernegg S, Li M, Varney M, Osborne PB, Reid CA, Halgamuge S, Petrou S.

Sci Rep. 2019 Jan 15;9(1):121. doi: 10.1038/s41598-018-37138-w.

6.

Cannabis and Mood Disorders.

Lucatch AM, Coles AS, Hill KP, George TP.

Curr Addict Rep. 2018 Sep;5(3):336-345. doi: 10.1007/s40429-018-0214-y. Epub 2018 May 10.

PMID:
30643708
7.

A preliminary investigation of lung availability of cannabinoids by smoking marijuana or dabbing BHO and decarboxylation rate of THC- and CBD-acids.

Hädener M, Vieten S, Weinmann W, Mahler H.

Forensic Sci Int. 2019 Jan 6. pii: S0379-0738(18)30847-8. doi: 10.1016/j.forsciint.2018.12.021. [Epub ahead of print]

PMID:
30638755
8.

9-Tetrahydrocannabinol, a major marijuana component, enhances the anesthetic effect of pentobarbital through the CB1 receptor.

Kimura T, Takaya M, Usami N, Watanabe K, Yamamoto I.

Forensic Toxicol. 2019;37(1):207-214. doi: 10.1007/s11419-018-0457-2. Epub 2018 Nov 24.

9.

Preclinical safety and efficacy of cannabidivarin for early life seizures.

Huizenga MN, Sepulveda-Rodriguez A, Forcelli PA.

Neuropharmacology. 2019 Jan 8. pii: S0028-3908(18)30678-6. doi: 10.1016/j.neuropharm.2019.01.002. [Epub ahead of print]

PMID:
30633929
10.

Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer.

Pellati F, Borgonetti V, Brighenti V, Biagi M, Benvenuti S, Corsi L.

Biomed Res Int. 2018 Dec 4;2018:1691428. doi: 10.1155/2018/1691428. eCollection 2018. Review.

11.

Special Considerations and Assessment in Patients with Multiple Sclerosis.

Maitin IB, Cruz E.

Phys Med Rehabil Clin N Am. 2018 Aug;29(3):473-481. doi: 10.1016/j.pmr.2018.03.003. Epub 2018 May 8. Review.

PMID:
30626509
12.

Cannabidiol in Anxiety and Sleep: A Large Case Series.

Shannon S, Lewis N, Lee H, Hughes S.

Perm J. 2019;23. pii: 18-041. doi: 10.7812/TPP/18-041.

13.

Why marijuana is headed for the mainstream.

Reinke T.

Manag Care. 2018 Dec;27(12):31.

14.

Epidiolex (Cannabidiol): A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes.

Chen JW, Borgelt LM, Blackmer AB.

Ann Pharmacother. 2019 Jan 8:1060028018822124. doi: 10.1177/1060028018822124. [Epub ahead of print]

PMID:
30616356
15.

Blood-brain barrier disturbances in diabetes-associated dementia: Therapeutic potential for cannabinoids.

Brook E, Mamo J, Wong R, Al-Salami H, Falasca M, Lam V, Takechi R.

Pharmacol Res. 2019 Jan 4;141:291-297. doi: 10.1016/j.phrs.2019.01.009. [Epub ahead of print] Review.

PMID:
30616019
16.

Validation of a liquid chromatography-tandem mass spectrometry method for analyzing cannabinoids in oral fluid.

Sobolesky PM, Smith BE, Hubbard JA, Stone J, Fitzgerald RL.

Clin Chim Acta. 2019 Jan 4. pii: S0009-8981(19)30002-6. doi: 10.1016/j.cca.2019.01.002. [Epub ahead of print]

PMID:
30615854
17.

Cannabinoid concentrations in confiscated cannabis samples and in whole blood and urine after smoking CBD-rich cannabis as a "tobacco substitute".

Hädener M, Gelmi TJ, Martin-Fabritius M, Weinmann W, Pfäffli M.

Int J Legal Med. 2019 Jan 5. doi: 10.1007/s00414-018-01994-y. [Epub ahead of print]

PMID:
30612324
18.

Adenosine A2A-Cannabinoid CB1 Receptor Heteromers in the Hippocampus: Cannabidiol Blunts Δ9-Tetrahydrocannabinol-Induced Cognitive Impairment.

Aso E, Fernández-Dueñas V, López-Cano M, Taura J, Watanabe M, Ferrer I, Luján R, Ciruela F.

Mol Neurobiol. 2019 Jan 4. doi: 10.1007/s12035-018-1456-3. [Epub ahead of print]

PMID:
30610611
19.

Tempering aversive/traumatic memories with cannabinoids: a review of evidence from animal and human studies.

Lisboa SF, Vila-Verde C, Rosa J, Uliana DL, Stern CAJ, Bertoglio LJ, Resstel LB, Guimaraes FS.

Psychopharmacology (Berl). 2019 Jan 2. doi: 10.1007/s00213-018-5127-x. [Epub ahead of print] Review.

PMID:
30604182
20.

Cannabidiol.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

Supplemental Content

Loading ...
Support Center